polatuzumab vedotin + obinutuzumab + cyclophosphamide + doxorubicin + prednisone

This is a **five-drug combination regimen** containing polatuzumab vedotin, obinutuzumab, cyclophosphamide, doxorubicin, and prednisone. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b on B cells to deliver the cytotoxic agent monomethyl auristatin E (MMAE). Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody, promoting B-cell lysis through direct cell death and antibody-dependent cytotoxicity. Cyclophosphamide and doxorubicin are small molecule chemotherapeutics, acting as an alkylating agent and a topoisomerase II inhibitor, respectively. Prednisone is a glucocorticoid with anti-inflammatory and immunosuppressant effects. The combination is being investigated, primarily in clinical trials, for previously untreated diffuse large B-cell lymphoma (DLBCL), aiming to improve efficacy by pairing the targeted activity of polatuzumab vedotin and obinutuzumab with a chemotherapy backbone[4][2].